<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Vet Res</journal-id><journal-id journal-id-type="iso-abbrev">Vet. Res</journal-id><journal-id journal-id-type="pmc-domain-id">892</journal-id><journal-id journal-id-type="pmc-domain">vetres</journal-id><journal-title-group><journal-title>Veterinary Research</journal-title></journal-title-group><issn pub-type="ppub">0928-4249</issn><issn pub-type="epub">1297-9716</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC4495609</article-id><article-id pub-id-type="pmcid-ver">PMC4495609.1</article-id><article-id pub-id-type="pmcaid">4495609</article-id><article-id pub-id-type="pmcaiid">4495609</article-id><article-id pub-id-type="pmid">26155935</article-id><article-id pub-id-type="doi">10.1186/s13567-015-0199-7</article-id><article-id pub-id-type="publisher-id">199</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Recent advances in <italic toggle="yes">Brucella abortus</italic> vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Dorneles</surname><given-names initials="EMS">Elaine MS</given-names></name><address><email>selesdorneles@yahoo.com.br</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sriranganathan</surname><given-names initials="N">Nammalwar</given-names></name><address><email>nathans@vt.edu</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Lage</surname><given-names initials="AP">Andrey P.</given-names></name><address><email>alage@vet.ufmg.br</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Departamento de Medicina Veterin&#225;ria Preventiva, Escola de Veterin&#225;ria, Laborat&#243;rio de Bacteriologia Aplicada, Universidade Federal de Minas Gerais, Belo Horizonte, MG Brazil </aff><aff id="Aff2"><label/>Department of Biomedical Sciences and Pathobiology, Center for Molecular Medicine and Infectious Diseases, Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA USA </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>46</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">247594</issue-id><elocation-id>76</elocation-id><history><date date-type="received"><day>21</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>5</day><month>5</month><year>2015</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>07</month><year>2015</year></date></event><event event-type="pmc-live"><date><day>09</day><month>07</month><year>2015</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-17 16:25:42.910"><day>17</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; Dorneles et al. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13567_2015_Article_199.pdf"/><abstract id="Abs1"><p><italic toggle="yes">Brucella abortus</italic> vaccines play a central role in bovine brucellosis control/eradication programs and have been successfully used worldwide for decades. Strain 19 and RB51 are the approved <italic toggle="yes">B. abortus</italic> vaccines strains most commonly used to protect cattle against infection and abortion. However, due to some drawbacks shown by these vaccines much effort has been undertaken for the development of new vaccines, safer and more effective, that could also be used in other susceptible species of animals. In this paper, we present a review of the main aspects of the vaccines that have been used in the brucellosis control over the years and the current research advances in the development of new <italic toggle="yes">B. abortus</italic> vaccines.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Table of contents</title><p><list list-type="order"><list-item><p>Introduction</p></list-item><list-item><p>Vaccines, vaccination and their use in brucellosis control and eradication programs</p></list-item><list-item><p>S19 vaccine</p></list-item><list-item><p>RB51 vaccine strain</p></list-item><list-item><p>45/20 vaccine</p></list-item><list-item><p>SR82 vaccine strain</p></list-item><list-item><p>Vaccination with recombinant genes, proteins, vectors and <italic toggle="yes">B. abortus</italic> recombinant mutants<list list-type="simple"><list-item><label>7.1.</label><p>DNA vaccines</p></list-item><list-item><label>7.2.</label><p>Subunit vaccines</p></list-item><list-item><label>7.3.</label><p>Vector vaccines</p></list-item><list-item><label>7.4.</label><p><italic toggle="yes">B. abortus</italic> recombinant mutants</p></list-item></list></p></list-item><list-item><p>Other <italic toggle="yes">B. abortus</italic> potential vaccines</p></list-item><list-item><p>Conclusions</p></list-item><list-item><p>Abbreviations</p></list-item><list-item><p>Competing interests</p></list-item><list-item><p>Authors&#8217; contributions</p></list-item><list-item><p>Acknowledgements</p></list-item><list-item><p>References</p></list-item></list></p></sec><sec id="Sec2"><title>1. Introduction</title><p><italic toggle="yes">B. abortus</italic> is the main causative agent of brucellosis in cattle, causing abortion and infertility in adult animals [<xref ref-type="bibr" rid="CR1">1</xref>]. Bovine brucellosis is a worldwide zoonotic disease, endemic in some regions of the world such as Latin America, Middle East, Africa and Asia [<xref ref-type="bibr" rid="CR1">1</xref>] and responsible for large economic losses due to animal and human health problems.</p><p>Due to public health importance of brucellosis and the damage that it causes to the livestock industry, much effort has been expended to control and eradicate the disease in cattle. The development of an efficacious vaccine for brucellosis control/eradication has been a challenge for scientists for many years. Despite enormous advances and the development of <italic toggle="yes">B. abortus</italic> S19 and RB51 vaccines, the search for improved vaccines has never ends. Although the available vaccines are effective in controlling brucellosis, they have numerous drawbacks, such as interference with diagnostic tests, pathogenicity for humans, potential to cause abortion in pregnant animals, among others. In this paper, we present a review of the main aspects of the vaccines that have been used in the bovine brucellosis control and eradication over the years and some of the current advances in the research for a new <italic toggle="yes">B. abortus</italic> vaccine.</p></sec><sec id="Sec3"><title>2. Vaccines, vaccination and their use in brucellosis control and eradication programs</title><p>According to Schurig et al. [<xref ref-type="bibr" rid="CR2">2</xref>] and Ko and Splitter [<xref ref-type="bibr" rid="CR3">3</xref>], an ideal vaccine against brucellosis should possess the following characteristics: (i) be live and able to provide a strong type 1&#160;T helper immune response (Th1); (ii) do not induce antibodies that interfere with the serological tests employed in the diagnosis of infected cattle, regardless of route, dose of administration, age or sex of the animals; (iii) be attenuated and do not cause disease or persistent infection in immunized animals nor be pathogenic for humans; (iv) be able to induce a strong and long-lasting protection against systemic and uterine infection, besides preventing abortion, even in pregnant animals inoculated with a single dose; (v) do not lead to seroconversion on revaccination; (vi) be stable and do not revert virulence in vivo nor in vitro; and (vii) be inexpensive, easy to produce and to administer.</p><p>Even though we still do not have an ideal vaccine, vaccination with available vaccine strains remains the most successful method for the prevention and control of brucellosis in cattle, being a critical component of most brucellosis control and eradication programs throughout the world [<xref ref-type="bibr" rid="CR4">4</xref>]. Numerous countries have adopted control measures against bovine brucellosis in order to reduce the prevalence or eradicate the disease from domestic livestock, in an effort to prevent transmission to humans and mitigate economic losses. Vaccination of female calves is the central point of any brucellosis control program, since it has performed well in the reduction of disease prevalence, therefore useful at the disease control stage. Considering that vaccination alone is not enough to control and eradicate the disease, it should be associated with continuous elimination of infected animals, as they are the source of new infections. Thus, besides vaccination, most bovine brucellosis eradicate programs also include test&#8211;and&#8211;slaughter policies, surveillance and hygiene measures [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p>The aim of vaccination is the reduction of susceptibly individuals in the population and the success of any vaccination program depends mainly on the effectiveness of the vaccine used and its coverage in the target population. Vaccines against brucellosis have been evaluated with respect to their potency by three different approaches: (i) testing in laboratory animals or (ii) testing in natural hosts experimentally challenged and (iii) testing under natural conditions [<xref ref-type="bibr" rid="CR5">5</xref>]. Of these, test in natural hosts shows more significant response and is the only one able to measure the efficacy of <italic toggle="yes">B. abortus</italic> vaccines [<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref>]. In experimental studies of vaccine efficacy, vaccinated and non-vaccinated controls will receive a known infectious dose of a virulent <italic toggle="yes">B. abortus</italic> strain at the most susceptible period (mid-gestation), and the protection is measure by the ability of the vaccine in preventing abortion [<xref ref-type="bibr" rid="CR4">4</xref>]. However, it is important to emphasize that the experimentally obtained effectiveness may differ from field efficacy that can be influenced by other factors, such as nutrition, environmental stress, age at vaccination, vaccination management or immunological status [<xref ref-type="bibr" rid="CR4">4</xref>]. Besides, the above three classical methodologies, <italic toggle="yes">B. abortus</italic> vaccines could also be assessed by measuring the immune responses and determination of correlates of protection by mathematical modeling. The identification of protection markers can be an useful approach to screen vaccine candidates whether validated by vaccine potency tests [<xref ref-type="bibr" rid="CR8">8</xref>]. Since experiments involving challenge of pregnant cattle are very expensive, time-consuming and requires large animal biosafety level 3 facilities, the rational way for the future of <italic toggle="yes">B. abortus</italic> vaccines testing and development could be the characterization and identification of the correlates of protection.</p><p>Another important aspect related to the success of brucellosis control programs is the quality of the vaccine used. Despite the cost of the vaccine being just one fraction of the total cost of a control program, its quality will affect directly and dramatically the outcome of the program. Assessing the quality of live <italic toggle="yes">Brucella</italic> vaccines is usually based on in vitro criteria, including physico-chemical and microbiological in vitro tests as to purity, dissociation, and determination of pH, humidity and count of viable bacteria [<xref ref-type="bibr" rid="CR9">9</xref>]. Recently, genetic stability has also been proposed as an additional criterion in assessing of the quality of <italic toggle="yes">Brucella</italic> spp. vaccines [<xref ref-type="bibr" rid="CR10">10</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref>]. Although less frequently, immunogenicity in mouse can also be included in <italic toggle="yes">Brucella</italic> vaccines tests, however not having cutoff points (protection zone) defined for RB51 vaccine [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>] and as mouse immune system does not accurately represent bovine immune system, it is very difficult to use such data.</p><p>Attenuated <italic toggle="yes">B. abortus</italic> strains have demonstrated the best results in the prevention of bovine brucellosis. <italic toggle="yes">B. abortus</italic> live modified vaccines are highly effective in decreasing transmission and production losses caused by brucellosis, but are less effective at preventing infection by field strains [<xref ref-type="bibr" rid="CR4">4</xref>]. Since, abortion is the key for the brucellosis transmission in cattle, a vaccine that can effectively prevent abortion is able to reduce disease transmission and largely reduce economic losses caused by the disease. Immunization with live modified <italic toggle="yes">B. abortus</italic> vaccines is generally performed in young female calves in a single dose by intramuscular or subcutaneous injection [<xref ref-type="bibr" rid="CR5">5</xref>]. However, in zones of high prevalence of brucellosis, massive vaccination, including adult cows, is performed.</p><p>It is also important to take into account that although cattle are the main target of the vaccination against <italic toggle="yes">B. abortus</italic> within bovine brucellosis control and eradication programs, they are not the unique species infected by this agent. Goats, feral swine, elks, bison and other hosts can also be infected by <italic toggle="yes">B. abortus</italic> and some of them are even able to sustain the disease, being considered an important source of the re-emergency of the disease in cattle [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p>Only a few vaccines have been used massively in cattle immunization against <italic toggle="yes">B. abortus,</italic> S19, RB51, 45/20 and SR82, being S19 and RB51 the most widely used vaccines [<xref ref-type="bibr" rid="CR4">4</xref>]. However, many <italic toggle="yes">B. abortus</italic> vaccine candidates have been developed, including DNA, subunit, recombinant <italic toggle="yes">B. abortus</italic> and recombinant vector vaccines. All of them are evaluated principally in mouse model [<xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR46">46</xref>], and with a few exceptions, the majority of these new vaccines, have not been tested in cattle or were not protective in cattle, the target species.</p></sec><sec id="Sec4"><title>3. S19 vaccine</title><p>Strain 19 is a live attenuated vaccine and the first <italic toggle="yes">B. abortus</italic> vaccine to be used extensively for bovine brucellosis control [<xref ref-type="bibr" rid="CR47">47</xref>]. In USA, this vaccine was used for more than five decades from 1941 and is still being used in several other countries [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p><italic toggle="yes">Brucella abortus</italic> S19 was isolated in 1923 from milk of a Jersey cow by Dr John Buck [<xref ref-type="bibr" rid="CR48">48</xref>]. This virulent culture was accidentally left out at room temperature for one year and when tested in guinea pigs showed lower virulence compared with previous tests [<xref ref-type="bibr" rid="CR49">49</xref>]. Subsequently, S19 showed to be highly successful in immunization of calves [<xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR50">50</xref>]. The efficacy of <italic toggle="yes">B. abortus</italic> S19 was proved by experimental tests in cattle [<xref ref-type="bibr" rid="CR47">47</xref>,<xref ref-type="bibr" rid="CR51">51</xref>] and under field conditions [<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR52">52</xref>]. Its main characteristics are stable low pathogenicity, relatively high immunogenicity, and moderate antigenicity [<xref ref-type="bibr" rid="CR53">53</xref>]. Strain 19 is a smooth attenuated <italic toggle="yes">B. abortus</italic> biovar 1 that induces antibody response that cannot be distinguished from the antibody response induced by infection with field strains [<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR50">50</xref>]. The lipopolysaccharide (LPS) O-side chain is an immunodominant antigen to which the majority of antibodies resulting from S19 immunization or natural infection are directed [<xref ref-type="bibr" rid="CR54">54</xref>]. Antibody titers resulting from vaccination may persist for a prolonged period in a small proportion of vaccinated calves: approximately two animals per 100 000 calfhood vaccinated ones [<xref ref-type="bibr" rid="CR54">54</xref>]. Residual antibody titers increase with the age at which the animal was vaccinated [<xref ref-type="bibr" rid="CR5">5</xref>], and to address this issue, vaccination is usually performed on young female calves between three and eight months of age [<xref ref-type="bibr" rid="CR47">47</xref>]. However, vaccination of this age group does not appear to significantly differ in immunity induced [<xref ref-type="bibr" rid="CR47">47</xref>]. Restriction on age of vaccination, due to the interference in the brucellosis diagnosis, is the main disadvantage of vaccination with S19. This has contributed greatly to their replacement by RB51 vaccine strain, which does not have this problem.</p><p>In calves, S19 vaccination can be performed with full dose [2.5 &#8211; 12&#8201;&#215;&#8201;10<sup>10</sup> colony forming units (CFU)], original dosage used in S19 classical experiments, or with reduced dosage (3&#8211;10&#8201;&#215;&#8201;10<sup>9</sup>&#160;CFU) to minimize residual antibody titers and to prevent occasional persistent vaccinal infection [<xref ref-type="bibr" rid="CR4">4</xref>]. After calfhood-vaccination, S19 is usually cleared from superficial cervical lymph node within 10 to 12&#160;weeks. Vaccination of adult cattle with S19, low dosage (0.3-3&#8201;&#215;&#8201;10<sup>9</sup>&#160;CFU), was also successfully employed in infected herds [<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR56">56</xref>]. S19-adult vaccination was tested as a strategy to be used in infected herds in order to reduce abortions and subsequently brucellosis transmission; however, it was discontinued because vaccination of pregnant animals can cause abortion and mainly because of the persistence of vaccinal antibodies [<xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR57">57</xref>].</p><p>In general, after calfhood vaccination, S19 does not persist in the reproductive tracts of mature heifers and does not cause abortion in these animals [<xref ref-type="bibr" rid="CR54">54</xref>]. Nonetheless, even with markedly infrequent occurrence, some cattle remain chronically infected and may abort and excrete the vaccine strain in the milk. Another disadvantage of S19 vaccination includes the fact that in some circumstances S19 can cause abortion in pregnant animals [<xref ref-type="bibr" rid="CR57">57</xref>]. After vaccination of cattle with one, two or three doses prior to breeding age, McDiarmid [<xref ref-type="bibr" rid="CR51">51</xref>] recovered S19 from 10% of milk samples and 1.5% of samples from cases of abortion. In males, calfhood S19 vaccination usually results in persistent antibody titers, testicular infection, and hence infertility [<xref ref-type="bibr" rid="CR58">58</xref>]. Furthermore, the vaccination of infected animals with S19 does not cure nor alter the normal course of the disease [<xref ref-type="bibr" rid="CR47">47</xref>,<xref ref-type="bibr" rid="CR50">50</xref>].</p><p>On the other hand, duration of immunity induced by S19 in cattle vaccinated as calves has proven to be quite long, reaching almost the entire productive lifespan of the animal [<xref ref-type="bibr" rid="CR47">47</xref>,<xref ref-type="bibr" rid="CR51">51</xref>]. The immunity in cattle vaccinated between 6 and 8&#160;months of age does not decrease from the first through the fifth pregnancy [<xref ref-type="bibr" rid="CR47">47</xref>,<xref ref-type="bibr" rid="CR51">51</xref>]. Moreover, revaccination experiments with S19 and killed <italic toggle="yes">B. abortus</italic> vaccines demonstrated no apparent benefit in cattle-challenge experiments compared with just S19-calfhood immunization [<xref ref-type="bibr" rid="CR47">47</xref>], despite McDiarmid [<xref ref-type="bibr" rid="CR51">51</xref>] having observed a small gain from S19 revaccination. Under field conditions 82 to 95% of vaccinated cattle have been shown to have complete protection against infection with virulent strains [<xref ref-type="bibr" rid="CR50">50</xref>]. However, it has also been demonstrated that the effectiveness of the vaccine decreases proportionally with an increasing dose of bacterial exposure [<xref ref-type="bibr" rid="CR47">47</xref>,<xref ref-type="bibr" rid="CR50">50</xref>].</p><p>Regarding the immune response triggered by S19 vaccination, most of our knowledge comes from mice studies, which have been shown a strong Th1 immune response with production of IFN-&#947; and high levels of antigen-specific CD4<sup>+</sup> and granzyme B-secreting CD8<sup>+</sup> T-cell responses [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p>Being pathogenic to man, the utilization of S19 requires safety training of the personal involved and the use of personal protection equipment as gloves, long sleeve coats, protection glasses, and N95 masks.</p></sec><sec id="Sec5"><title>4. RB51 vaccine strain</title><p><italic toggle="yes">B. abortus</italic> strain RB51 is a rough rifampicin-resistant strain, which exhibited a lack of expression of the LPS O-side chains (OPS) [<xref ref-type="bibr" rid="CR59">59</xref>]. RB51 vaccine strain was developed in 1982 by Prof. Gerhardt Schurig&#8217;s group and is derived from a virulent smooth <italic toggle="yes">B. abortus</italic> biovar 1 strain 2308 [<xref ref-type="bibr" rid="CR59">59</xref>]. This is a natural mutant derived by a serial passages on media containing subinibitory concentrations of rifampicin or penicillin and by selecting single colonies with rough morphology [<xref ref-type="bibr" rid="CR59">59</xref>]. The rough characteristic is stable during in vitro and in vivo passages and does not revert to virulent phenotype [<xref ref-type="bibr" rid="CR59">59</xref>].</p><p>The protection against abortion and infection induced by RB51 vaccination in cattle has been sufficiently demonstrated under experimental conditions [<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR60">60</xref>,<xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR64">64</xref>]. Also, the use of RB51 is highly effective under field conditions, in herds with high and low brucellosis prevalence [<xref ref-type="bibr" rid="CR62">62</xref>,<xref ref-type="bibr" rid="CR63">63</xref>].</p><p>The literature shows that calves vaccinated with RB51 at three, five and seven months of age are protected against infection and abortion [<xref ref-type="bibr" rid="CR64">64</xref>], as well as heifers vaccinated at age of 10 or 24&#160;months, after challenge with the virulent <italic toggle="yes">B. abortus</italic> 2308 [<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR60">60</xref>]. Nevertheless, it has been suggested that under experimental circumstances the vaccination with S19 is slightly (not significant) more efficacious than RB51 [<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR64">64</xref>]. After vaccination, RB51 is usually cleared from calf superficial cervical lymph node within 6 to 10&#160;weeks [<xref ref-type="bibr" rid="CR64">64</xref>]. RB51 is considered more attenuated than S19, based on results of clearance and histologic examination of infected tissues of vaccinated animals.</p><p>In general, the recommended dosage for RB51 calfhood vaccination is 1.0 &#8211; 3.4&#8201;&#215;&#8201;10<sup>10</sup>&#160;CFU [<xref ref-type="bibr" rid="CR4">4</xref>]. Protection against <italic toggle="yes">B. abortus</italic> infection is similar through the suggested dosage, although higher antibody titers and longer persistence of bacteria had been associated with the full dose (3.4&#8201;&#215;&#8201;10<sup>10</sup>&#160;CFU) [<xref ref-type="bibr" rid="CR7">8</xref>]. Reduced dosage (1&#8201;&#215;&#8201;10<sup>9</sup>&#160;CFU), generally recommended for adult animals, also protects against infection and abortion caused by virulent 2308 [<xref ref-type="bibr" rid="CR61">61</xref>]. Despite RB51 having highly reduced abortifacient characteristics [<xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR65">65</xref>], it is not completely safe for pregnant cow, mainly when full dose is administrated [<xref ref-type="bibr" rid="CR66">66</xref>]. However, some results indicate that non-vaccinated cattle and cattle vaccinated with S19 as calves can be safely vaccinated with RB51 (full dose) during the pregnancy [<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR68">68</xref>]. Furthermore, data indicates that RB51 vaccination is a safe procedure also for males [<xref ref-type="bibr" rid="CR69">69</xref>].</p><p>In addition, as S19 vaccine, RB51 can cause infection in humans especially immunosuppressed individuals [<xref ref-type="bibr" rid="CR70">70</xref>]. RB51 is resistant to rifampicin, one of the antibiotics of choice in the treatment of human brucellosis, and failure to be detected by routine serological tests are the two most important points one has to be aware during diagnosis and treatment of humans. Therefore, the same protective measures recommended for S19 also applies to RB51 use.</p><p>Because of the rough phenotype, RB51 does not induce the production of anti-OPS antibodies in immunized animals, overcoming the serologic problems observed after S19 vaccination [<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR61">61</xref>]. Consequently, RB51 vaccinated cattle can be easily and accurately differentiated from naturally infected animals, allowing the effective use of the test-and-slaughter and vaccination policies simultaneously. Vaccination with RB51 does not induce antibodies detectable by routine serologic brucellosis diagnostic tests, even after S19 calfhood vaccination and multiple RB51 boosters or use of full dose of RB51 (3.4&#8201;&#215;&#8201;10<sup>10</sup>&#160;CFU) [<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR68">68</xref>]. However, RB51-specific antibodies can be detected by dot enzyme-linked immunosorbent assay or ELISA using killed RB51 antigens [<xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR72">72</xref>], until approximately 12&#160;weeks after vaccination, with the peak occurring four weeks after vaccination or revaccination with decreasing titers after ten weeks [<xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR73">73</xref>]. Interestingly, S19-vaccinated cattle exhibit higher titers against RB51 antigens in ELISA than animals vaccinated with RB51, probably due to persistence of S19, which may result in high levels of cross-reacting antibodies against RB51 antigens [<xref ref-type="bibr" rid="CR73">73</xref>].</p><p>So far, there are no experiments that evaluated the duration of immunity, but Olsen and Stoffregen [<xref ref-type="bibr" rid="CR4">4</xref>] suggest that a booster vaccination is required between 4 and 5&#160;years of age to maintain high levels of protection after RB51 calfhood vaccination. Also, RB51 revaccination has been recommended six months and one year after calfhood vaccination in northern Mexico [<xref ref-type="bibr" rid="CR74">74</xref>]. Nonetheless, findings from blastogenic response of CD4<sup>+</sup> and CD8<sup>+</sup> T-cells and the production of IFN-&#611; and IL-4 by the lymphocyte subsets six months after RB51 revaccination indicate that there was no increase or improvement in the immunological response resulting from RB51-revaccination of adult cattle [<xref ref-type="bibr" rid="CR75">75</xref>]. Even though, RB51 revaccination may still be considered as a tool for increasing herd immunity, since not all animals are completely protected after primary immunization [<xref ref-type="bibr" rid="CR50">50</xref>]. Furthermore, it has been demonstrated that RB51 induces a strong Th1 cellular immune response with production of IFN-&#947; and CD8<sup>+</sup> specific cytotoxic cells, but not IL-4 after vaccination of mice [<xref ref-type="bibr" rid="CR76">76</xref>].</p></sec><sec id="Sec6"><title>5. 45/20 vaccine</title><p>This vaccine is prepared with heat-killed <italic toggle="yes">B. abortus</italic> biovar 1 strain 45/20 combined with oil adjuvant [<xref ref-type="bibr" rid="CR77">77</xref>]. The 45/20 is a rough <italic toggle="yes">B. abortus,</italic> derived of smooth strain 45/0 after 20 passages through guinea pigs [<xref ref-type="bibr" rid="CR78">78</xref>]. This bacterin was used in some European Union countries for <italic toggle="yes">B. abortus</italic> control replacing S19, in order to eliminate the problems related to the induction of antibodies interfering in the routine diagnosis of infection [<xref ref-type="bibr" rid="CR5">5</xref>]. However, data of experimental efficacy and immunologic response are contradictory and mostly show the superiority of vaccination with S19 [<xref ref-type="bibr" rid="CR79">79</xref>,<xref ref-type="bibr" rid="CR80">80</xref>]. Furthermore, its use has some drawbacks such as the use of oil adjuvant, needing of repeat vaccination and reversion to smooth strain when used as a live vaccine [<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR78">78</xref>]. Furthermore, some studies have also indicated that 45/20 is not completely free of the O-side chain [<xref ref-type="bibr" rid="CR81">81</xref>], hence this vaccine can induce antibodies detectable by routine serologic tests employed in the diagnosis of bovine brucellosis. The variability in reported protection, along with unpredictable serological effects and the occurrence of reactions at the site of vaccine injection in some animals led to the interruption of the use of 45/20 vaccine.</p></sec><sec id="Sec7"><title>6. SR82 vaccine strain</title><p>The SR82 strain is a <italic toggle="yes">B. abortus</italic> biovar 6 live attenuated vaccine used since 1974 by the former Union of Soviet Socialist Republics (USSR) for bovine brucellosis control [<xref ref-type="bibr" rid="CR82">82</xref>]. This vaccine agglutinates in both rough and smooth anti-sera, but does not induce positive response in brucellosis agglutination tests [<xref ref-type="bibr" rid="CR82">82</xref>,<xref ref-type="bibr" rid="CR83">83</xref>]. Moreover, SR82 induced protection level similar to S19, after challenge with virulent <italic toggle="yes">B. abortus</italic>, and it has been shown to be effective under field conditions [<xref ref-type="bibr" rid="CR82">82</xref>,<xref ref-type="bibr" rid="CR83">83</xref>]. Currently the SR82 strain is still massively used in the Russian Federation, Azerbaijan, Tejikistan and other countries in the region [<xref ref-type="bibr" rid="CR82">82</xref>].</p></sec><sec id="Sec8"><title>7. Vaccination with recombinant genes, proteins, vectors and <italic toggle="yes">B. abortus</italic> recombinant mutants</title><p>Classically and historically the vaccines used in the bovine brucellosis control are live attenuated vaccines produced from spontaneously attenuated or randomly selected strains. Nonetheless, the numerous advances in genomics, proteomics, recombinant DNA technology and even in vaccinology, allowed the exploration of other tools for the development of safer vaccines, without drawbacks observed in classical vaccines. In this context, several studies aimed to develop, test the efficacy or assess the immulogical responses of the <italic toggle="yes">B. abortus</italic> genetically engineered vaccines (recombinant genes, proteins, vectors and modified <italic toggle="yes">B. abortus</italic> strains) have been performed essentially in mice. However, with a few exceptions the majority of these recombinant vaccines, have not been tested or did not protect cattle, their target species. Moreover, it is important to take into account that recombinant vaccines, especially non-living ones, have limitations regarding economic viability, need for multiple doses and the need for combination of antigens.</p><sec id="Sec9"><title>7.1. DNA vaccines</title><p>DNA vaccines offer the possibility of inducing both cellular and humoral responses, expression of antigens is prolonged, they have better stability and do not require refrigeration under storage. Therefore, several antigens have been explored for their value as DNA vaccines against <italic toggle="yes">B. abortus</italic> challenge, providing various levels of protection. DNA vaccines encoding ribosomal <italic toggle="yes">L7/L12,</italic> lumazine synthase (<italic toggle="yes">BLS</italic>), <italic toggle="yes">P39</italic> (a putative periplasmic binding protein), <italic toggle="yes">Omp16</italic> (outer membrane protein) and <italic toggle="yes">BAB1_0278</italic> genes have demonstrated to confer protection against <italic toggle="yes">B. abortus</italic> challenge in mice [<xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR42">42</xref>]. Moreover, Cu/Zn superoxide dismutase (Cu-Zn SOD) DNA vaccine induced a protection level similar to the one induced by RB51 [<xref ref-type="bibr" rid="CR25">25</xref>]. All these genes also proved capable of eliciting a desirable cellular immune response in mice [<xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR42">42</xref>]. In contrast, plasmid DNA carrying the <italic toggle="yes">BAB1_0263</italic> and bacterioferritin (<italic toggle="yes">BFR</italic>) genes did not induce significant level of protection against challenge with virulent <italic toggle="yes">B. abortus</italic> in mice.</p><p>Combined DNA vaccines have also demonstrated their ability to protect better against challenge. DNA vaccines of genes coding for an immundominant <italic toggle="yes">Brucella-</italic>antigen (BCSP31) and promising <italic toggle="yes">Brucella-</italic>antigens (SOD and L7/L12) provided significantly better protection than S19 in mice [<xref ref-type="bibr" rid="CR32">32</xref>]. This combined DNA vaccine also elicited significantly higher cytotoxic response (granzyme B&#8211;producing CD8<sup>+</sup> T cells) compared to S19-vaccinated mice [<xref ref-type="bibr" rid="CR32">32</xref>]. Likewise, divalent fusion DNA vaccine encoding <italic toggle="yes">L7/L12</italic> and <italic toggle="yes">Omp16</italic> genes also proved to be effective and able to elicit a strong T-cell proliferative response and induce a large amount of IFN-&#947; producing T cells [<xref ref-type="bibr" rid="CR27">27</xref>]. Additionally, data showed that combination of these <italic toggle="yes">B. abortus</italic> genes (<italic toggle="yes">BCSP31, SOD</italic> and <italic toggle="yes">L7/L12</italic>) with <italic toggle="yes">Mycobacterium tuberculosis</italic> (<italic toggle="yes">Ag85B, MPT64</italic>, and <italic toggle="yes">MPT83</italic>) or <italic toggle="yes">Mycobacterium bovis</italic> (<italic toggle="yes">Ag85B, MPT64,</italic> and <italic toggle="yes">MPT83</italic>) genes are very promising for both agents [<xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR34">34</xref>]. DNA vaccine containing six genes encoding immunodominant antigens from <italic toggle="yes">M. bovis</italic> and <italic toggle="yes">B. abortus</italic> induced protection comparable to S19 and better than Bacillus Calmette-Guerin (BCG) vaccine in cattle, suggesting that this is a highly promising vaccine for both diseases [<xref ref-type="bibr" rid="CR34">34</xref>]. Combined DNA vaccine containing <italic toggle="yes">M. tuberculosis</italic> and <italic toggle="yes">B. abortus</italic> genes with added IL-12 adjuvant system showed that besides the high level of protection, IL-12 acts as an adjuvant to enhance protective immunity against <italic toggle="yes">M. tuberculosis</italic> and <italic toggle="yes">B. abortus</italic> in challenge mice [<xref ref-type="bibr" rid="CR33">33</xref>]. Conversely, results suggest that a SOD DNA vaccine fused to IL-2 did not improve protection efficacy [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p>However, despite some of <italic toggle="yes">B. abortus</italic> DNA vaccine candidates have shown very promising results in mice, the need of at least four booster vaccinations to be effective as well as the high cost for use in large animals, make this type of vaccine impractical for cattle, the main target of brucellosis vaccination. Moreover, excluding mouse studies practically no DNA vaccine has been explored in natural hosts.</p></sec><sec id="Sec10"><title>7.2. Subunit vaccines</title><p>Many of the same antigens tested as DNA vaccines have also been evaluated as potential antigens for subunit vaccines (L7/L12 ribosomal protein; P39; BLS; Omp16; Cu/Zn SOD) [<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR40">40</xref>]. The outer membrane proteins (OMPs) of <italic toggle="yes">B. abortus</italic>, potential immunogenic antigens, have been widely explored as subunit vaccines [<xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR45">45</xref>]. Unlipidated recombinant Omp16 and Omp19, and recombinant Omp25 liposome encapsulated gave protection comparable to S19 in vaccinated mice following challenge [<xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR45">45</xref>]. Also, Omp28 subunit vaccine increased resistance against challenge with virulent <italic toggle="yes">B. abortus</italic> but at lower level than live attenuated vaccines [<xref ref-type="bibr" rid="CR43">43</xref>].</p><p>Similarly, flagellar proteins have been screened in search for a subunit vaccine antigen candidate. Five flagellar genes, although <italic toggle="yes">Brucella</italic> spp. are non-motile, (<italic toggle="yes">BAB1_0260</italic> (FlgJ); <italic toggle="yes">BAB2_0122</italic> (FliN); <italic toggle="yes">BAB2_0150</italic>; <italic toggle="yes">BAB2_1086</italic>; <italic toggle="yes">BAB2_1093</italic>) were evaluated for their ability to induce humoral and cell-mediated responses and protect mice against <italic toggle="yes">B. abortus</italic> challenge [<xref ref-type="bibr" rid="CR84">84</xref>]. Of these, FlgJ and FliN were found to be protective antigens that produced humoral and cell-mediated responses in mice.</p><p>Moreover, recombinant proteins of other proven or putative pathogenesis-associated genes such as L7/12, BLS, rSurA and rDnaK induced different levels of protective immunity and cellular immune response in mice against brucellosis [<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR31">31</xref>]. Whereas, dihydrolipoamide succinyltransferase (rE2o) and cysteine synthase A (rCysK) provided partial protection against <italic toggle="yes">B. abortus</italic> challenge and induced primarily Th2 type of immune response [<xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR46">46</xref>]. Furthermore, CobB, AsnC and P39 elicit protective immunity similarly to Cu/Zn SOD and S19, which is marked by both humoral and cellular immune responses [<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR85">85</xref>]. Also, Cu/Zn SOD recombinant protein (liposomes encapsulated) confers resistance in mice, further increased upon co-immunization with recombinant IL-18 [<xref ref-type="bibr" rid="CR40">40</xref>]. In contrast, BAB1_0560, BAB1_1108, BAB2_0059 (VirB10), BAB2_0191, BAB2_0423 (GntR) and BRF protein vaccines did not induce protective immune response [<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR85">85</xref>].</p><p>The potential use of <italic toggle="yes">B. abortus</italic> subunit vaccines under field conditions is very limited, although some encouraging results showed. The requirement of multiple boosters, adjuvants and combination of several antigens makes it economically unsuitable for cattle. Moreover, it is important to consider that the response observed in mice may not reflect the protection achieved in natural hosts after vaccination. Furthermore, to generate a strong and protective immune response that can mimic the natural infection from a combination of few proteins of the pathogen is a hard and complex challenge.</p></sec><sec id="Sec11"><title>7.3. Vector vaccines</title><p>Alternatively, genes encoding immunodominant <italic toggle="yes">B. abortus</italic> antigens can be introduced into attenuated viruses or bacteria that serve as vector vaccines. <italic toggle="yes">B. abortus</italic> genes have been successfully expressed in viruses (Semliki Forest virus and Vaccinia virus) and bacteria (<italic toggle="yes">Escherichia coli, Ochrobactrum anthropi, Lactococcus lactis</italic>, <italic toggle="yes">Salmonella enterica</italic> subsp <italic toggle="yes">enterica</italic> serovar Typhimurium and <italic toggle="yes">B. abortus</italic>) [<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR86">86</xref>]. <italic toggle="yes">Escherichia coli, O. anthropi</italic> (plus unmethylated CpG motifs) and <italic toggle="yes">L. lactis</italic> expressing Cu/Zn SOD antigen of <italic toggle="yes">B. abortus</italic> were able to elicit a Th1 immune response and to protect mice following challenge with virulent <italic toggle="yes">B. abortus</italic> [<xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR86">86</xref>]. Likewise, Semliki Forest virus-based vector carrying RNA encoding <italic toggle="yes">Brucella</italic> translation initiation factor 3 (IF3) showed a significant level of protection against a challenge with <italic toggle="yes">B. abortus</italic> 2308 in mice [<xref ref-type="bibr" rid="CR35">35</xref>]. L7/L12 protein carried by <italic toggle="yes">S. enterica</italic> serovar typhimurium but not by Vaccinia virus conferred protective efficacy and immunogenicity [<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR38">38</xref>]. Also, vaccinia virus carrying 18-kDa OMP of <italic toggle="yes">B. abortus</italic> were not able to protect mice against a challenge with the virulent strain <italic toggle="yes">B. abortus</italic> 2308 [<xref ref-type="bibr" rid="CR87">87</xref>].</p><p>The expression of <italic toggle="yes">B. abortus</italic> antigens on viral or bacterial vectors is a superior alternative to DNA and subunit vaccines, as it closely mimics the natural infection, allowing the modulation of the host immune response and the multiplication of the initial number of antigen copies within the host. However, despite not having some of the inconveniences observed in non-living vaccines, as multiple doses, need for adjuvant and high cost, other organisms expressing <italic toggle="yes">B. abortus</italic> proteins still need the perfect grouping of antigens, expressed in high amount to be effective. The amount of foreign protein expressed by the carrier organism needs to be able to promote a specific protection. Moreover, the use of viral platform implies in small chance that the vector DNA is integrated into the genome of the host cell. In addition, although promising most of these above vaccines have failed or have not been tested in cattle, the target species, so no conclusion could be drawn at this time.</p></sec><sec id="Sec12"><title><italic toggle="yes">7.4. B. abortus</italic> recombinant mutants</title><p>Another focus of research for new vaccines to protect against <italic toggle="yes">B. abortus</italic> infection has been the construction of RB51 recombinant mutants, which retain the rough phenotype and attenuation but have improved characteristics such as immunogenicity and protection against a challenge [<xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>]. Hence, some studies have shown that the complementation of RB51 with a functional <italic toggle="yes">wbo</italic>A gene (RB51<italic toggle="yes">Wbo</italic>A), which lead to the expression of O-side chain in its cytoplasm, or the overexpression of Cu/Zn SOD protein (RB51SOD) results in significant enhancement of the vaccine efficacy against challenge with virulent <italic toggle="yes">B. abortus</italic> in mice [<xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref>]. Furthermore, the combination of these two genes in a single RB51 strain (RB51SOD/<italic toggle="yes">wbo</italic>A) also significantly increased the protective ability of this RB51 recombinant vaccine in mice and did not alter its desirable characteristics [<xref ref-type="bibr" rid="CR19">19</xref>]. Nonetheless, this RB51-recombinant strain was not as effective as the parental RB51 strain in calfhood vaccination of bison after challenge with 2308 [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p>Besides RB51, <italic toggle="yes">B. abortus</italic> strain 2308 has also been tested as recombinant mutant vaccine; the deletion of the gene <italic toggle="yes">znuA,</italic> important protein for survival and normal growth under low Zn<sup>2+</sup> concentrations, generated a mutant capable of conferring protection similar to S19 or RB51 against challenge with parental 2308 in mice [<xref ref-type="bibr" rid="CR30">30</xref>]. Experiments in natural hosts, cattle, showed that the double gene deletion (<italic toggle="yes">htrA cycL</italic>) PHE1 was attenuated in the bovine host when compared to the virulent parental 2308 [<xref ref-type="bibr" rid="CR88">88</xref>]. However, due the absence of a standard challenge study using this potential vaccine, the meaning of such data is unclear. Recombinant mutants based on deletion of ABC transporter ATPase (<italic toggle="yes">BAB1_0542</italic>) or phosphoglycerate kinase (<italic toggle="yes">pgk</italic>) gene of <italic toggle="yes">B. abortus</italic> 2308 also showed protection against challenge with virulent strain in mice and the critical role of these genes for full bacterial virulence [<xref ref-type="bibr" rid="CR89">89</xref>,<xref ref-type="bibr" rid="CR90">90</xref>]. In addition to the virulence attenuation, it is desired that these <italic toggle="yes">B. abortus</italic> mutants also show no interference with the diagnostics tests, hence genes associated to the smooth phenotype have been explored in the generation of deleted vaccines. Rough mutant generated by <italic toggle="yes">wboA</italic> gene deletion of S19 protected mice against challenge with 2308 and did not induce abortion in pregnant sheep, showing promising results to be explored in the future development of rough vaccines [<xref ref-type="bibr" rid="CR91">91</xref>].</p><p>The improvement of the existing <italic toggle="yes">B. abortus</italic> vaccines or the creation of new attenuated vaccines by deletion or complementation of some genes seems to be the most promising direction to find a safer and more efficient substitute for the known <italic toggle="yes">B. abortus</italic> vaccines. Modified live vaccines are highly effective in comparison to killed vaccines. This is most likely due to strong and protective cellular immune response induced by live vaccines [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref>]. The use of this platform avoids the main disadvantages related to the non-living vaccines, as multiple delivery, low immunogenicity, need for adjuvants and high cost. Furthermore, <italic toggle="yes">B. abortus</italic> strains, even if genetically modified, can colonize, be immunogenic, and therefore perfectly simulate the natural infection. They are able to multiply within animals for a short period expressing in vivo protective antigens. The major advantage of this approach over the use of vectors is that recombinant mutants share most of proteins with <italic toggle="yes">B. abortus</italic> field strains, whereas carrier organisms are able of expressing only few <italic toggle="yes">Brucella</italic> antigens. However, a real concern on <italic toggle="yes">B. abortus</italic> mutant strains is the presence of antibiotic selection marker. The antibiotic marker is used in the screening of transformed clones, but it is not desirable in the final vaccine due to the potential of spreading antibiotic resistance genes. Options, as an RB51 leucine auxotroph, have been explored to avoid this issue [<xref ref-type="bibr" rid="CR92">92</xref>]. Additionally, so far, there is no data available to exclude the possibility that these live mutants will not have similar safety and diagnostic issues as live strains, especially if made from smooth strains. Also, to move forwards in the control of bovine brucellosis, these recombinant mutants must be evaluated in cattle and other target animal species. There is still a worldwide need for a vaccine that is safe and highly efficacious in natural hosts, since the transmission of disease occurs from cattle to people. The results obtained in mice, although favorable for some vaccines, have to be interpreted according to their limitations, as they cannot be directly extrapolated to cattle.</p><p>On another point of view about the usefulness of <italic toggle="yes">B. abortus</italic> mutant as vaccines, S19 and RB51, the widely used <italic toggle="yes">B. abortus</italic> vaccines, has been investigated as potential vectors for heterologous protein expression, mainly using protective antigens important for other diseases of veterinary interest [<xref ref-type="bibr" rid="CR93">93</xref>&#8211;<xref ref-type="bibr" rid="CR96">96</xref>]. In this context, multivalent recombinant RB51 vaccines expressing <italic toggle="yes">Neospora caninum</italic> or <italic toggle="yes">M. bovis</italic> proteins have been shown to induce antigen specific immune response to heterologous antigens and, in the case of <italic toggle="yes">N. caninum,</italic> was also achieved significant level of protection in mice [<xref ref-type="bibr" rid="CR93">93</xref>,<xref ref-type="bibr" rid="CR94">94</xref>]. Likewise, S19 carrying the genes encoding for the heterologous antigens of <italic toggle="yes">Babebia bovis</italic> or <italic toggle="yes">M. bovis</italic> demonstrated successful specific cellular immune response to recombinant proteins in mouse model [<xref ref-type="bibr" rid="CR95">95</xref>,<xref ref-type="bibr" rid="CR96">96</xref>]. These above bivalent live modified <italic toggle="yes">B. abortus</italic> candidate vaccines need further evaluation as to their ability to induce protective immune response as well lack of interference in the diagnostic tests.</p></sec></sec><sec id="Sec13"><title>8. Other <italic toggle="yes">B. abortus</italic> potential vaccines</title><p>Besides <italic toggle="yes">B. abortus</italic> recombinants vaccines, also vaccines based on outer membrane vesicles (OMVs) has been exploited as an acellular alternative to live vaccines [<xref ref-type="bibr" rid="CR97">97</xref>]. OMVs are bilayer membrane vesicles release by Gram-negative and Gram-positive bacteria, which have been associated to many processes such as release of virulent factors, DNA transfer, regulation of host immune response and survival in the host cell [<xref ref-type="bibr" rid="CR98">98</xref>]. <italic toggle="yes">B. abortus</italic> OMVs are mainly composed for outer membrane proteins (Omps) and have been associated with modulation of host immune response by inhibition of TNF-&#945; and IL-8 response, inhibition of IFN-&#947; induced expression of MHC class II molecules on human monocytes and increase in expression of adhesion molecules [<xref ref-type="bibr" rid="CR97">97</xref>&#8211;<xref ref-type="bibr" rid="CR99">99</xref>]. A <italic toggle="yes">Brucella melitensis</italic> vaccine based on OMVs has been tested and showed promising results in BALB/c mice [<xref ref-type="bibr" rid="CR100">100</xref>]. Furthermore, it is already available a vaccine based on OMVs, against meningococcus serogroup B (<italic toggle="yes">Neisseria meningitides</italic>) in some countries as Cuba, Norway and New Zealand [<xref ref-type="bibr" rid="CR97">97</xref>]. Therefore, it is possible to speculate that an OMV vaccine against <italic toggle="yes">B. abortus</italic> has a great potential to be considered as part of the continuous efforts to reach safer and more effective <italic toggle="yes">B. abortus</italic> vaccine. Nonetheless, due to its high cost and laborious production, OMV is a more suitable approach for human vaccines, being impracticable for cattle bearing in mind the technologies currently available.</p></sec><sec id="Sec14"><title>9. Conclusions</title><p>Vaccination is a determinant strategy for brucellosis control and eradication programs, therefore it has been the target of innumerous studies over decades. Nowadays, some effective vaccines are available to control the disease in cattle. S19 and RB51 are the officially approved <italic toggle="yes">B. abortus</italic> vaccine strains more widely and successfully used to prevent bovine brucellosis worldwide. However, due to some side effects shown by these current vaccines, plus the advances in recombinant DNA technology and the lack of a vaccine for humans, there is an on going extensive efforts focused on the development of new and better vaccines. Engineered vaccines have the potential to be the future of the bovine and human brucellosis control, but many studies are still needed to develop a better vaccine than the current vaccines in terms of safety, efficacy and other desirable characteristics. Moreover, it is important to consider that, mainly non-living recombinant vaccines, also present important issues, as the requirement of multiple boosters, adjuvants, and optimal combination of antigens, besides usually inducing poor cellular immune response. In addition, although the excellent results observed for some recombinant vaccines in mice, very few of these candidate vaccines have been evaluated in cattle. The recent studies indicate that the future of a new <italic toggle="yes">B. abortus</italic> vaccine will be the construction of directed mutants, which exclude the drawbacks and simultaneously increase immunogenic characteristics presented by S19 and RB51. Furthermore, concerning the immune response induced after S19 and RB51 vaccination in cattle, as well as after RB51 revaccination, very little is understood. Efforts to find out the principal characteristics of the immune response triggered in cattle by the two most used and successful <italic toggle="yes">B. abortus</italic> vaccine strains are essential to try to establish an ideal vaccine. The definition of immune markers correlated with protection, by mathematical modeling or evaluation of the immune response in vaccine - challenge studies - would be very helpful in the screening of <italic toggle="yes">B. abortus</italic> candidate vaccines.</p></sec></body><back><glossary><title>10. Abbreviations</title><def-list><def-item><term>Th1</term><def><p>Type 1&#160;T helper</p></def></def-item><def-item><term>LPS</term><def><p>Lipopolysaccharide</p></def></def-item><def-item><term>CFU</term><def><p>Colony forming units</p></def></def-item><def-item><term>OPS</term><def><p>O-side chains</p></def></def-item><def-item><term>OMP</term><def><p>Outer membrane protein</p></def></def-item><def-item><term>Cu-Zn SOD</term><def><p>Cu/Zn superoxide dismutase</p></def></def-item><def-item><term>BFR</term><def><p>Bacterioferritin</p></def></def-item><def-item><term>BCG</term><def><p>Bacillus Calmette-Guerin</p></def></def-item><def-item><term>rCysK</term><def><p>Cysteine synthase A</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>11. Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>12. Authors&#8217; contributions</bold></p><p>EMSD wrote the paper. APL and NS critically reviewed the manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>13. Acknowledgements</title><p>A.P. Lage were indebted to Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico &#8211; CNPq for his fellowship. EMSD thanks CNPq and Capes (Ci&#234;ncia Sem Fronteiras 8808&#8211;13) for her fellowship as well. APL lab was supported by CNPq, Funda&#231;&#227;o de Amparo &#224; Pesquisa do Estado de Minas Gerais - Fapemig and FEP &#8211; MVZ Coordena&#231;&#227;o Preventiva.</p></ack><ref-list id="Bib1"><title>14. References</title><ref id="CR1"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Corbel</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Elberg</surname><given-names>SS</given-names></name><name name-style="western"><surname>Cosivi</surname><given-names>O</given-names></name></person-group><source>Brucellosis in humans and animals</source><year>2006</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schurig</surname><given-names>G</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>S</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name></person-group><article-title>Brucella abortus vaccine strain RB51: a brief review</article-title><source>Arch Med Vet</source><year>1995</year><volume>27</volume><fpage>19</fpage><lpage>22</lpage></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>J</given-names></name><name name-style="western"><surname>Splitter</surname><given-names>GA</given-names></name></person-group><article-title>Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans</article-title><source>Clin Microbiol Rev</source><year>2003</year><volume>16</volume><fpage>65</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1128/CMR.16.1.65-78.2003</pub-id><pub-id pub-id-type="pmid">12525425</pub-id><pub-id pub-id-type="pmcid">PMC145300</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olsen</surname><given-names>SC</given-names></name><name name-style="western"><surname>Stoffregen</surname><given-names>WS</given-names></name></person-group><article-title>Essential role of vaccines in brucellosis control and eradication programs for livestock</article-title><source>Expert Rev Vaccines</source><year>2005</year><volume>4</volume><fpage>915</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1586/14760584.4.6.915</pub-id><pub-id pub-id-type="pmid">16372886</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Nicoletti</surname><given-names>P</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Nielsen</surname><given-names>K</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>JR</given-names></name></person-group><article-title>Vaccination</article-title><source>Animal Brucellosis</source><year>1990</year><publisher-loc>Boca Raton</publisher-loc><publisher-name>CRC Press</publisher-name></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poester</surname><given-names>FP</given-names></name><name name-style="western"><surname>Goncalves</surname><given-names>VS</given-names></name><name name-style="western"><surname>Paixao</surname><given-names>TA</given-names></name><name name-style="western"><surname>Santos</surname><given-names>RL</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>SC</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name><name name-style="western"><surname>Lage</surname><given-names>AP</given-names></name></person-group><article-title>Efficacy of strain RB51 vaccine in heifers against experimental brucellosis</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>5327</fpage><lpage>5334</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.04.020</pub-id><pub-id pub-id-type="pmid">16713034</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olsen</surname><given-names>SC</given-names></name><name name-style="western"><surname>Bricker</surname><given-names>B</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>MV</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>AE</given-names></name><name name-style="western"><surname>Cheville</surname><given-names>NF</given-names></name></person-group><article-title>Responses of cattle to two dosages of Brucella abortus strain RB51: serology, clearance and efficacy</article-title><source>Res Vet Sci</source><year>1999</year><volume>66</volume><fpage>101</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1053/rvsc.1998.0251</pub-id><pub-id pub-id-type="pmid">10208887</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thakur</surname><given-names>A</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>LE</given-names></name><name name-style="western"><surname>Jungersen</surname><given-names>G</given-names></name></person-group><article-title>Immune markers and correlates of protection for vaccine induced immune responses</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>4907</fpage><lpage>4920</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.05.049</pub-id><pub-id pub-id-type="pmid">22658928</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miranda</surname><given-names>KL</given-names></name><name name-style="western"><surname>Dorneles</surname><given-names>EM</given-names></name><name name-style="western"><surname>Pauletti</surname><given-names>RB</given-names></name><name name-style="western"><surname>Poester</surname><given-names>FP</given-names></name><name name-style="western"><surname>Lage</surname><given-names>AP</given-names></name></person-group><article-title><italic toggle="yes">Brucella abortus</italic> S19 and RB51 vaccine immunogenicity test: evaluation of three mice (BALB/c, Swiss and CD-1&#174;) and two challenge strains (544 and 2308)</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>507</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.11.056</pub-id><pub-id pub-id-type="pmid">25498211</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Yoldi</surname><given-names>D</given-names></name><name name-style="western"><surname>Le Fleche</surname><given-names>P</given-names></name><name name-style="western"><surname>Marin</surname><given-names>CM</given-names></name><name name-style="western"><surname>De Miguel</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>PM</given-names></name><name name-style="western"><surname>Vergnaud</surname><given-names>G</given-names></name><name name-style="western"><surname>Lopez-Goni</surname><given-names>I</given-names></name></person-group><article-title>Assessment of genetic stability of Brucella melitensis Rev 1 vaccine strain by multiple-locus variable-number tandem repeat analysis</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>2858</fpage><lpage>2862</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.09.063</pub-id><pub-id pub-id-type="pmid">17050051</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miranda</surname><given-names>KL</given-names></name><name name-style="western"><surname>Poester</surname><given-names>FP</given-names></name><name name-style="western"><surname>Minharro</surname><given-names>S</given-names></name><name name-style="western"><surname>Dorneles</surname><given-names>EM</given-names></name><name name-style="western"><surname>Stynen</surname><given-names>AP</given-names></name><name name-style="western"><surname>Lage</surname><given-names>AP</given-names></name></person-group><article-title>Evaluation of Brucella abortus S19 vaccines commercialized in Brazil: immunogenicity, residual virulence and MLVA15 genotyping</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>3014</fpage><lpage>3018</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.04.054</pub-id><pub-id pub-id-type="pmid">23664986</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorneles</surname><given-names>EM</given-names></name><name name-style="western"><surname>de Faria</surname><given-names>AP</given-names></name><name name-style="western"><surname>Pauletti</surname><given-names>RB</given-names></name><name name-style="western"><surname>Santana</surname><given-names>JA</given-names></name><name name-style="western"><surname>Caldeira</surname><given-names>GA</given-names></name><name name-style="western"><surname>Heinemann</surname><given-names>MB</given-names></name><name name-style="western"><surname>Titze-de-Almeida</surname><given-names>R</given-names></name><name name-style="western"><surname>Lage</surname><given-names>AP</given-names></name></person-group><article-title>Genetic stability of Brucella abortus S19 and RB51 vaccine strains by multiple locus variable number tandem repeat analysis (MLVA16)</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>4856</fpage><lpage>4859</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.07.063</pub-id><pub-id pub-id-type="pmid">23933375</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliveira</surname><given-names>SC</given-names></name><name name-style="western"><surname>Harms</surname><given-names>JS</given-names></name><name name-style="western"><surname>Banai</surname><given-names>M</given-names></name><name name-style="western"><surname>Splitter</surname><given-names>GA</given-names></name></person-group><article-title>Recombinant Brucella abortus proteins that induce proliferation and gamma-interferon secretion by CD4+ T cells from Brucella-vaccinated mice and delayed-type hypersensitivity in sensitized guinea pigs</article-title><source>Cell Immunol</source><year>1996</year><volume>172</volume><fpage>262</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1006/cimm.1996.0241</pub-id><pub-id pub-id-type="pmid">8964089</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliveira</surname><given-names>SC</given-names></name><name name-style="western"><surname>Splitter</surname><given-names>GA</given-names></name></person-group><article-title>Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection</article-title><source>Vaccine</source><year>1996</year><volume>14</volume><fpage>959</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(96)00018-7</pub-id><pub-id pub-id-type="pmid">8873388</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Toth</surname><given-names>TE</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name></person-group><article-title>Cloning and sequencing of yajC and secD homologs of Brucella abortus and demonstration of immune responses to YajC in mice vaccinated with B. abortus RB51</article-title><source>Infect Immun</source><year>1998</year><volume>66</volume><fpage>5684</fpage><lpage>5691</lpage><pub-id pub-id-type="pmid">9826342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.66.12.5684-5691.1998</pub-id><pub-id pub-id-type="pmcid">PMC108718</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>Cravero</surname><given-names>S</given-names></name><name name-style="western"><surname>Calvert</surname><given-names>CL</given-names></name><name name-style="western"><surname>Toth</surname><given-names>TE</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name><name name-style="western"><surname>Rossetti</surname><given-names>OL</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name></person-group><article-title>Characterization of specific immune responses of mice inoculated with recombinant vaccinia virus expressing an 18-kilodalton outer membrane protein of Brucella abortus</article-title><source>Clin Diagn Lab Immunol</source><year>2000</year><volume>7</volume><fpage>114</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">10618289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/cdli.7.1.114-118.2000</pub-id><pub-id pub-id-type="pmcid">PMC95834</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Buccolo</surname><given-names>LS</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name></person-group><article-title>Complementation of Brucella abortus RB51 with a functional wboA gene results in O-antigen synthesis and enhanced vaccine efficacy but no change in rough phenotype and attenuation</article-title><source>Infect Immun</source><year>2000</year><volume>68</volume><fpage>3927</fpage><lpage>3932</lpage><pub-id pub-id-type="doi">10.1128/IAI.68.7.3927-3932.2000</pub-id><pub-id pub-id-type="pmid">10858205</pub-id><pub-id pub-id-type="pmcid">PMC101669</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cravero</surname><given-names>S</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name></person-group><article-title>Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51</article-title><source>Infect Immun</source><year>2000</year><volume>68</volume><fpage>3286</fpage><lpage>3289</lpage><pub-id pub-id-type="doi">10.1128/IAI.68.6.3286-3289.2000</pub-id><pub-id pub-id-type="pmid">10816475</pub-id><pub-id pub-id-type="pmcid">PMC97582</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>Contreras</surname><given-names>A</given-names></name><name name-style="western"><surname>Sanakkayala</surname><given-names>N</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name></person-group><article-title>Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice</article-title><source>Vet Microbiol</source><year>2004</year><volume>102</volume><fpage>237</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2004.07.001</pub-id><pub-id pub-id-type="pmid">15327798</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name></person-group><article-title>Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu, Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type</article-title><source>Infect Immun</source><year>2002</year><volume>70</volume><fpage>2535</fpage><lpage>2543</lpage><pub-id pub-id-type="doi">10.1128/IAI.70.5.2535-2543.2002</pub-id><pub-id pub-id-type="pmid">11953393</pub-id><pub-id pub-id-type="pmcid">PMC127893</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Mariri</surname><given-names>A</given-names></name><name name-style="western"><surname>Tibor</surname><given-names>A</given-names></name><name name-style="western"><surname>Mertens</surname><given-names>P</given-names></name><name name-style="western"><surname>De Bolle</surname><given-names>X</given-names></name><name name-style="western"><surname>Michel</surname><given-names>P</given-names></name><name name-style="western"><surname>Godefroid</surname><given-names>J</given-names></name><name name-style="western"><surname>Walravens</surname><given-names>K</given-names></name><name name-style="western"><surname>Letesson</surname><given-names>JJ</given-names></name></person-group><article-title>Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant</article-title><source>Infect Immun</source><year>2001</year><volume>69</volume><fpage>4816</fpage><lpage>4822</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.8.4816-4822.2001</pub-id><pub-id pub-id-type="pmid">11447155</pub-id><pub-id pub-id-type="pmcid">PMC98569</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Mariri</surname><given-names>A</given-names></name><name name-style="western"><surname>Tibor</surname><given-names>A</given-names></name><name name-style="western"><surname>Mertens</surname><given-names>P</given-names></name><name name-style="western"><surname>De Bolle</surname><given-names>X</given-names></name><name name-style="western"><surname>Michel</surname><given-names>P</given-names></name><name name-style="western"><surname>Godfroid</surname><given-names>J</given-names></name><name name-style="western"><surname>Walravens</surname><given-names>K</given-names></name><name name-style="western"><surname>Letesson</surname><given-names>JJ</given-names></name></person-group><article-title>Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp</article-title><source>Infect Immun</source><year>2001</year><volume>69</volume><fpage>6264</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.10.6264-6270.2001</pub-id><pub-id pub-id-type="pmid">11553569</pub-id><pub-id pub-id-type="pmcid">PMC98760</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Velikovsky</surname><given-names>CA</given-names></name><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name><name name-style="western"><surname>Giambartolomei</surname><given-names>GH</given-names></name><name name-style="western"><surname>Goldbaum</surname><given-names>FA</given-names></name><name name-style="western"><surname>Estein</surname><given-names>S</given-names></name><name name-style="western"><surname>Bowden</surname><given-names>RA</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>L</given-names></name><name name-style="western"><surname>Fossati</surname><given-names>CA</given-names></name><name name-style="western"><surname>Spitz</surname><given-names>M</given-names></name></person-group><article-title>A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice</article-title><source>Infect Immun</source><year>2002</year><volume>70</volume><fpage>2507</fpage><lpage>2511</lpage><pub-id pub-id-type="doi">10.1128/IAI.70.5.2507-2511.2002</pub-id><pub-id pub-id-type="pmid">11953389</pub-id><pub-id pub-id-type="pmcid">PMC127889</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Velikovsky</surname><given-names>CA</given-names></name><name name-style="western"><surname>Goldbaum</surname><given-names>FA</given-names></name><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name><name name-style="western"><surname>Estein</surname><given-names>S</given-names></name><name name-style="western"><surname>Bowden</surname><given-names>RA</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>L</given-names></name><name name-style="western"><surname>Fossati</surname><given-names>CA</given-names></name><name name-style="western"><surname>Giambartolomei</surname><given-names>GH</given-names></name></person-group><article-title>Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used</article-title><source>Infect Immun</source><year>2003</year><volume>71</volume><fpage>5750</fpage><lpage>5755</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.10.5750-5755.2003</pub-id><pub-id pub-id-type="pmid">14500496</pub-id><pub-id pub-id-type="pmcid">PMC201088</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Onate</surname><given-names>AA</given-names></name><name name-style="western"><surname>Cespedes</surname><given-names>S</given-names></name><name name-style="western"><surname>Cabrera</surname><given-names>A</given-names></name><name name-style="western"><surname>Rivers</surname><given-names>R</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>A</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>C</given-names></name><name name-style="western"><surname>Folch</surname><given-names>H</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>E</given-names></name></person-group><article-title>A DNA vaccine encoding Cu, Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice</article-title><source>Infect Immun</source><year>2003</year><volume>71</volume><fpage>4857</fpage><lpage>4861</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.9.4857-4861.2003</pub-id><pub-id pub-id-type="pmid">12933826</pub-id><pub-id pub-id-type="pmcid">PMC187304</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baloglu</surname><given-names>S</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name><name name-style="western"><surname>Toth</surname><given-names>TE</given-names></name></person-group><article-title>Immune responses of mice to vaccinia virus recombinants expressing either Listeria monocytogenes partial listeriolysin or Brucella abortus ribosomal L7/L12 protein</article-title><source>Vet Microbiol</source><year>2005</year><volume>109</volume><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2005.04.011</pub-id><pub-id pub-id-type="pmid">15941627</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>D</given-names></name><name name-style="western"><surname>Ni</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mao</surname><given-names>L</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice</article-title><source>Infect Immun</source><year>2006</year><volume>74</volume><fpage>2734</fpage><lpage>2741</lpage><pub-id pub-id-type="doi">10.1128/IAI.74.5.2734-2741.2006</pub-id><pub-id pub-id-type="pmid">16622210</pub-id><pub-id pub-id-type="pmcid">PMC1459688</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrews</surname><given-names>E</given-names></name><name name-style="western"><surname>Salgado</surname><given-names>P</given-names></name><name name-style="western"><surname>Folch</surname><given-names>H</given-names></name><name name-style="western"><surname>Onate</surname><given-names>A</given-names></name></person-group><article-title>Vaccination with live Escherichia coli expressing Brucella abortus Cu/Zn superoxide-dismutase: II. Induction of specific CD8+ cytotoxic lymphocytes and sensitized CD4+ IFN-gamma-producing cell</article-title><source>Microbiol Immunol</source><year>2006</year><volume>50</volume><fpage>389</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1111/j.1348-0421.2006.tb03805.x</pub-id><pub-id pub-id-type="pmid">16714846</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez-Smith</surname><given-names>A</given-names></name><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>E</given-names></name><name name-style="western"><surname>Onate</surname><given-names>A</given-names></name></person-group><article-title>Evaluation of Brucella abortus DNA vaccine by expression of Cu-Zn superoxide dismutase antigen fused to IL-2</article-title><source>Immunobiology</source><year>2006</year><volume>211</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2005.09.004</pub-id><pub-id pub-id-type="pmid">16446171</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Becker</surname><given-names>T</given-names></name><name name-style="western"><surname>Walters</surname><given-names>N</given-names></name><name name-style="western"><surname>Pascual</surname><given-names>DW</given-names></name></person-group><article-title>Deletion of znuA virulence factor attenuates Brucella abortus and confers protection against wild-type challenge</article-title><source>Infect Immun</source><year>2006</year><volume>74</volume><fpage>3874</fpage><lpage>3879</lpage><pub-id pub-id-type="doi">10.1128/IAI.01957-05</pub-id><pub-id pub-id-type="pmid">16790759</pub-id><pub-id pub-id-type="pmcid">PMC1489696</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delpino</surname><given-names>MV</given-names></name><name name-style="western"><surname>Estein</surname><given-names>SM</given-names></name><name name-style="western"><surname>Fossati</surname><given-names>CA</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>PC</given-names></name><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name></person-group><article-title>Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>6721</fpage><lpage>6729</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.07.002</pub-id><pub-id pub-id-type="pmid">17686554</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>DH</given-names></name><name name-style="western"><surname>Hu</surname><given-names>XD</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name></person-group><article-title>A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses</article-title><source>DNA Cell Biol</source><year>2007</year><volume>26</volume><fpage>435</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1089/dna.2006.0552</pub-id><pub-id pub-id-type="pmid">17570767</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>DH</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Hu</surname><given-names>XD</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name></person-group><article-title>A combined DNA vaccine enhances protective immunity against Mycobacterium tuberculosis and Brucella abortus in the presence of an IL-12 expression vector</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>6744</fpage><lpage>6754</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.06.061</pub-id><pub-id pub-id-type="pmid">17681650</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>XD</given-names></name><name name-style="western"><surname>Yu</surname><given-names>DH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>ST</given-names></name><name name-style="western"><surname>Li</surname><given-names>SX</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name></person-group><article-title>A combined DNA vaccine provides protective immunity against Mycobacterium bovis and Brucella abortus in cattle</article-title><source>DNA Cell Biol</source><year>2009</year><volume>28</volume><fpage>191</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1089/dna.2008.0790</pub-id><pub-id pub-id-type="pmid">19364278</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cabrera</surname><given-names>A</given-names></name><name name-style="western"><surname>Saez</surname><given-names>D</given-names></name><name name-style="western"><surname>Cespedes</surname><given-names>S</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>E</given-names></name><name name-style="western"><surname>Onate</surname><given-names>A</given-names></name></person-group><article-title>Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB/c mice</article-title><source>Immunobiology</source><year>2009</year><volume>214</volume><fpage>467</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2008.11.016</pub-id><pub-id pub-id-type="pmid">19150742</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olsen</surname><given-names>SC</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>NN</given-names></name></person-group><article-title>Immune responses and protection against experimental challenge after vaccination of bison with Brucella abortus strain RB51 or RB51 overexpressing superoxide dismutase and glycosyltransferase genes</article-title><source>Clin Vaccine Immunol</source><year>2009</year><volume>16</volume><fpage>535</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1128/CVI.00419-08</pub-id><pub-id pub-id-type="pmid">19176693</pub-id><pub-id pub-id-type="pmcid">PMC2668271</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasquevich</surname><given-names>KA</given-names></name><name name-style="western"><surname>Estein</surname><given-names>SM</given-names></name><name name-style="western"><surname>Garcia Samartino</surname><given-names>C</given-names></name><name name-style="western"><surname>Zwerdling</surname><given-names>A</given-names></name><name name-style="western"><surname>Coria</surname><given-names>LM</given-names></name><name name-style="western"><surname>Barrionuevo</surname><given-names>P</given-names></name><name name-style="western"><surname>Fossati</surname><given-names>CA</given-names></name><name name-style="western"><surname>Giambartolomei</surname><given-names>GH</given-names></name><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name></person-group><article-title>Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection</article-title><source>Infect Immun</source><year>2009</year><volume>77</volume><fpage>436</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1128/IAI.01151-08</pub-id><pub-id pub-id-type="pmid">18981242</pub-id><pub-id pub-id-type="pmcid">PMC2612246</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Luo</surname><given-names>D</given-names></name><name name-style="western"><surname>Xing</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Protection of mice from Brucella infection by immunization with attenuated Salmonella enterica serovar typhimurium expressing A L7/L12 and BLS fusion antigen of Brucella</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>5214</fpage><lpage>5219</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.06.075</pub-id><pub-id pub-id-type="pmid">19596411</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasquevich</surname><given-names>KA</given-names></name><name name-style="western"><surname>Ibanez</surname><given-names>AE</given-names></name><name name-style="western"><surname>Coria</surname><given-names>LM</given-names></name><name name-style="western"><surname>Garcia Samartino</surname><given-names>C</given-names></name><name name-style="western"><surname>Estein</surname><given-names>SM</given-names></name><name name-style="western"><surname>Zwerdling</surname><given-names>A</given-names></name><name name-style="western"><surname>Barrionuevo</surname><given-names>P</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>FS</given-names></name><name name-style="western"><surname>Seither</surname><given-names>C</given-names></name><name name-style="western"><surname>Warzecha</surname><given-names>H</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>SC</given-names></name><name name-style="western"><surname>Giambartolomei</surname><given-names>GH</given-names></name><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name></person-group><article-title>An oral vaccine based on U-Omp19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL-17 immune response in mice</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0016203</pub-id><pub-id pub-id-type="pmid">21264260</pub-id><pub-id pub-id-type="pmcid">PMC3021544</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singha</surname><given-names>H</given-names></name><name name-style="western"><surname>Mallick</surname><given-names>AI</given-names></name><name name-style="western"><surname>Jana</surname><given-names>C</given-names></name><name name-style="western"><surname>Fatima</surname><given-names>N</given-names></name><name name-style="western"><surname>Owais</surname><given-names>M</given-names></name><name name-style="western"><surname>Chaudhuri</surname><given-names>P</given-names></name></person-group><article-title>Co-immunization with interlukin-18 enhances the protective efficacy of liposomes encapsulated recombinant Cu-Zn superoxide dismutase protein against Brucella abortus</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>4720</fpage><lpage>4727</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.04.088</pub-id><pub-id pub-id-type="pmid">21565241</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>SK</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name></person-group><article-title>Immunogenicity and protective potential of a bacterially expressed recombinant dihydrolipoamide succinyltransferase (rE2o) of Brucella abortus in BALB/c mice</article-title><source>World J Microbiol Biotechnol</source><year>2012</year><volume>28</volume><fpage>2487</fpage><lpage>2495</lpage><pub-id pub-id-type="doi">10.1007/s11274-012-1056-8</pub-id><pub-id pub-id-type="pmid">22806154</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sislema-Egas</surname><given-names>F</given-names></name><name name-style="western"><surname>Cespedes</surname><given-names>S</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>P</given-names></name><name name-style="western"><surname>Retamal-Diaz</surname><given-names>A</given-names></name><name name-style="western"><surname>Saez</surname><given-names>D</given-names></name><name name-style="western"><surname>Onate</surname><given-names>A</given-names></name></person-group><article-title>Evaluation of protective effect of DNA vaccines encoding the BAB1_0263 and BAB1_0278 open reading frames of Brucella abortus in BALB/c mice</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>7286</fpage><lpage>7291</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.09.039</pub-id><pub-id pub-id-type="pmid">23026687</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DG</given-names></name><name name-style="western"><surname>Min</surname><given-names>W</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>MH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name></person-group><article-title>Protective effects of recombinantBrucella abortusOmp28 against infection with a virulent strain of Brucella abortus544 in mice</article-title><source>J Vet Sci</source><year>2012</year><volume>13</volume><fpage>287</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.4142/jvs.2012.13.3.287</pub-id><pub-id pub-id-type="pmid">23000585</pub-id><pub-id pub-id-type="pmcid">PMC3467404</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saez</surname><given-names>D</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>P</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>A</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>E</given-names></name><name name-style="western"><surname>Onate</surname><given-names>A</given-names></name></person-group><article-title>Oral immunization of mice with recombinant Lactococcus lactis expressing Cu, Zn superoxide dismutase of Brucella abortus triggers protective immunity</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>1283</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.12.088</pub-id><pub-id pub-id-type="pmid">22222868</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goel</surname><given-names>D</given-names></name><name name-style="western"><surname>Rajendran</surname><given-names>V</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>PC</given-names></name><name name-style="western"><surname>Bhatnagar</surname><given-names>R</given-names></name></person-group><article-title>Cell mediated immune response after challenge in Omp25 liposome immunized mice contributes to protection against virulent Brucella abortus 544</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>1231</fpage><lpage>1237</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.12.043</pub-id><pub-id pub-id-type="pmid">23273966</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>S</given-names></name><name name-style="western"><surname>Afley</surname><given-names>P</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name></person-group><article-title>Immunological responses to recombinant cysteine synthase A of Brucella abortus in BALB/c mice</article-title><source>World J Microbiol Biotechnol</source><year>2013</year><volume>29</volume><fpage>907</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1007/s11274-012-1247-3</pub-id><pub-id pub-id-type="pmid">23269507</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">Manthei CA (1959) Summary of controlled research with strain 19, Proceedings 63rd Ann Meet US Livestock Sanitary Association.</mixed-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buck</surname><given-names>JM</given-names></name></person-group><article-title>Studies on vaccination during calfhood to prevent bovine infectious abortion</article-title><source>J Agri Res</source><year>1930</year><volume>41</volume><fpage>667</fpage><lpage>689</lpage></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graves</surname><given-names>RR</given-names></name></person-group><article-title>The story of John M</article-title><source>Buck&#8217;s and Matilda&#8217;s contribution to the cattle industry J Am Vet Med Assoc</source><year>1943</year><volume>102</volume><fpage>193</fpage><lpage>195</lpage></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>FM</given-names></name><name name-style="western"><surname>Hooper</surname><given-names>JA</given-names></name></person-group><article-title>Brucella abortus strain 19 calfhood vaccination &#8211; a review</article-title><source>Southwest Vet</source><year>1976</year><volume>29</volume><fpage>219</fpage><lpage>225</lpage></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McDiarmid</surname><given-names>A</given-names></name></person-group><article-title>The degree and duration of immunity in cattle resulting from vaccination with S. 19 Br. abortus vaccine and its implication in the future control and eventual eradication of Brucellosis</article-title><source>Vet Rec</source><year>1957</year><volume>69</volume><fpage>877</fpage><lpage>879</lpage></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koh</surname><given-names>SH</given-names></name><name name-style="western"><surname>Morley</surname><given-names>FH</given-names></name></person-group><article-title>The effect of calfhood vaccination with strain 19 on the serological diagnosis and eradication of bovine brucellosis</article-title><source>Aust Vet J</source><year>1981</year><volume>57</volume><fpage>551</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1111/j.1751-0813.1981.tb00432.x</pub-id><pub-id pub-id-type="pmid">7340777</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mingle</surname><given-names>CK</given-names></name><name name-style="western"><surname>Manthei</surname><given-names>CA</given-names></name><name name-style="western"><surname>Jasmin</surname><given-names>AM</given-names></name></person-group><article-title>The stability of reduced virulence exhibited by Brucella abortus strain 19</article-title><source>J Am Vet Med Assoc</source><year>1941</year><volume>99</volume><fpage>203</fpage><lpage>205</lpage></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyer</surname><given-names>ME</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>CJ</given-names></name></person-group><article-title>Persistence of Brucella abortus, strain 19 infection in immunized cattle</article-title><source>Proc Annu Meet U S Anim Health Assoc</source><year>1969</year><volume>73</volume><fpage>159</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">4993565</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breitmeyer</surname><given-names>RE</given-names></name><name name-style="western"><surname>Hird</surname><given-names>DW</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>TE</given-names></name></person-group><article-title>Serologic and bacteriologic test results after adult vaccination with strain 19 in three dairy herds infected with brucellosis</article-title><source>J Am Vet Med Assoc</source><year>1992</year><volume>200</volume><fpage>806</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">1568926</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicoletti</surname><given-names>P</given-names></name></person-group><article-title>Prevalence and persistence of Brucella abortus strain 19 infections and prevalence of other biotypes in vaccinated adult dairy cattle</article-title><source>J Am Vet Med Assoc</source><year>1981</year><volume>178</volume><fpage>143</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">6782064</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corner</surname><given-names>LA</given-names></name><name name-style="western"><surname>Alton</surname><given-names>GG</given-names></name></person-group><article-title>Persistence of Brucella abortus strain 19 infection in adult cattle vaccinated with reduced doses</article-title><source>Res Vet Sci</source><year>1981</year><volume>31</volume><fpage>342</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">6805054</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>G</given-names></name><name name-style="western"><surname>Manthei</surname><given-names>CA</given-names></name><name name-style="western"><surname>Deyoe</surname><given-names>BL</given-names></name></person-group><article-title>Studies on Brucella abortus infection in bulls</article-title><source>Am J Vet Res</source><year>1963</year><volume>24</volume><fpage>1152</fpage><lpage>1157</lpage><pub-id pub-id-type="pmid">14081449</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name><name name-style="western"><surname>Roop</surname><given-names>RM</given-names><suffix>2nd</suffix></name><name name-style="western"><surname>Bagchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>S</given-names></name><name name-style="western"><surname>Buhrman</surname><given-names>D</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name></person-group><article-title>Biological properties of RB51; a stable rough strain of Brucella abortus</article-title><source>Vet Microbiol</source><year>1991</year><volume>28</volume><fpage>171</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/0378-1135(91)90091-S</pub-id><pub-id pub-id-type="pmid">1908158</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheville</surname><given-names>NF</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>MG</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>AE</given-names></name><name name-style="western"><surname>Tatum</surname><given-names>FM</given-names></name><name name-style="western"><surname>Halling</surname><given-names>SM</given-names></name></person-group><article-title>Immune responses and protection against infection and abortion in cattle experimentally vaccinated with mutant strains of Brucella abortus</article-title><source>Am J Vet Res</source><year>1993</year><volume>54</volume><fpage>1591</fpage><lpage>1597</lpage><pub-id pub-id-type="pmid">8250382</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olsen</surname><given-names>SC</given-names></name></person-group><article-title>Immune responses and efficacy after administration of a commercial Brucella abortus strain RB51 vaccine to cattle</article-title><source>Vet Ther</source><year>2000</year><volume>1</volume><fpage>183</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">19757581</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lord</surname><given-names>VR</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name><name name-style="western"><surname>Cherwonogrodzky</surname><given-names>JW</given-names></name><name name-style="western"><surname>Marcano</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Melendez</surname><given-names>GE</given-names></name></person-group><article-title>Field study of vaccination of cattle with Brucella abortus strains RB51 and 19 under high and low disease prevalence</article-title><source>Am J Vet Res</source><year>1998</year><volume>59</volume><fpage>1016</fpage><lpage>1020</lpage><pub-id pub-id-type="pmid">9706206</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorneles</surname><given-names>EM</given-names></name><name name-style="western"><surname>Santana</surname><given-names>JA</given-names></name><name name-style="western"><surname>Alves</surname><given-names>TM</given-names></name><name name-style="western"><surname>Pauletti</surname><given-names>RB</given-names></name><name name-style="western"><surname>Mol</surname><given-names>JP</given-names></name><name name-style="western"><surname>Heinemann</surname><given-names>MB</given-names></name><name name-style="western"><surname>Lage</surname><given-names>AP</given-names></name></person-group><article-title>Genetic stability of Brucella abortus isolates from an outbreak by multiple-locus variable-number tandem repeat analysis (MLVA16)</article-title><source>BMC Microbiol</source><year>2014</year><volume>14</volume><fpage>186</fpage><pub-id pub-id-type="doi">10.1186/1471-2180-14-186</pub-id><pub-id pub-id-type="pmid">25015840</pub-id><pub-id pub-id-type="pmcid">PMC4112982</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheville</surname><given-names>NF</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>SC</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>AE</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>MG</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>MV</given-names></name><name name-style="western"><surname>Florance</surname><given-names>AM</given-names></name></person-group><article-title>Effects of age at vaccination on efficacy of Brucella abortus strain RB51 to protect cattle against brucellosis</article-title><source>Am J Vet Res</source><year>1996</year><volume>57</volume><fpage>1153</fpage><lpage>1156</lpage><pub-id pub-id-type="pmid">8836366</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>MV</given-names></name><name name-style="western"><surname>Cheville</surname><given-names>NF</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>AE</given-names></name></person-group><article-title>Experimental infection of pregnant cattle with the vaccine candidate Brucella abortus strain RB51: pathologic, bacteriologic, and serologic findings</article-title><source>Vet Pathol</source><year>1996</year><volume>33</volume><fpage>682</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1177/030098589603300607</pub-id><pub-id pub-id-type="pmid">8952027</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>MV</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>SC</given-names></name><name name-style="western"><surname>Cheville</surname><given-names>NF</given-names></name></person-group><article-title>Safety and immunogenicity of Brucella abortus strain RB51 vaccine in pregnant cattle</article-title><source>Am J Vet Res</source><year>1997</year><volume>58</volume><fpage>472</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">9140553</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martins</surname><given-names>H</given-names></name><name name-style="western"><surname>Garin-Bastuji</surname><given-names>B</given-names></name><name name-style="western"><surname>Lima</surname><given-names>F</given-names></name><name name-style="western"><surname>Flor</surname><given-names>L</given-names></name><name name-style="western"><surname>Pina Fonseca</surname><given-names>A</given-names></name><name name-style="western"><surname>Boinas</surname><given-names>F</given-names></name></person-group><article-title>Eradication of bovine brucellosis in the Azores, Portugal-Outcome of a 5-year programme (2002&#8211;2007) based on test-and-slaughter and RB51 vaccination</article-title><source>Prev Vet Med</source><year>2009</year><volume>90</volume><fpage>80</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.prevetmed.2009.04.002</pub-id><pub-id pub-id-type="pmid">19439382</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samartino</surname><given-names>LE</given-names></name><name name-style="western"><surname>Fort</surname><given-names>M</given-names></name><name name-style="western"><surname>Gregoret</surname><given-names>R</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name></person-group><article-title>Use of Brucella abortus vaccine strain RB51 in pregnant cows after calfhood vaccination with strain 19 in Argentina</article-title><source>Prev Vet Med</source><year>2000</year><volume>45</volume><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/S0167-5877(00)00130-6</pub-id><pub-id pub-id-type="pmid">10821960</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edmonds</surname><given-names>MD</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name><name name-style="western"><surname>Samartino</surname><given-names>LE</given-names></name><name name-style="western"><surname>Hoyt</surname><given-names>PG</given-names></name><name name-style="western"><surname>Walker</surname><given-names>JV</given-names></name><name name-style="western"><surname>Hagius</surname><given-names>SD</given-names></name><name name-style="western"><surname>Elzer</surname><given-names>PH</given-names></name></person-group><article-title>Biosafety of Brucella abortus strain RB51 for vaccination of mature bulls and pregnant heifers</article-title><source>Am J Vet Res</source><year>1999</year><volume>60</volume><fpage>722</fpage><lpage>725</lpage><pub-id pub-id-type="pmid">10376900</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashford</surname><given-names>DA</given-names></name><name name-style="western"><surname>di Pietra</surname><given-names>J</given-names></name><name name-style="western"><surname>Lingappa</surname><given-names>J</given-names></name><name name-style="western"><surname>Woods</surname><given-names>C</given-names></name><name name-style="western"><surname>Noll</surname><given-names>H</given-names></name><name name-style="western"><surname>Neville</surname><given-names>B</given-names></name><name name-style="western"><surname>Weyant</surname><given-names>R</given-names></name><name name-style="western"><surname>Bragg</surname><given-names>SL</given-names></name><name name-style="western"><surname>Spiegel</surname><given-names>RA</given-names></name><name name-style="western"><surname>Tappero</surname><given-names>J</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>BA</given-names></name></person-group><article-title>Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>3435</fpage><lpage>3439</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.02.041</pub-id><pub-id pub-id-type="pmid">15308369</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olsen</surname><given-names>SC</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>MG</given-names></name><name name-style="western"><surname>Cheville</surname><given-names>NF</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>G</given-names></name></person-group><article-title>Experimental use of a dot-blot assay to measure serologic responses of cattle vaccinated with Brucella abortus strain RB51</article-title><source>J Vet Diagn Invest</source><year>1997</year><volume>9</volume><fpage>363</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1177/104063879700900404</pub-id><pub-id pub-id-type="pmid">9376424</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><mixed-citation publication-type="other">Nielsen K, Smith P, Yu W, Nicoletti P, Elzer P, Vigliocco A, Silva P, Bermudez R, Renteria T, Moreno F, Ruiz A, Massengill C, Muenks Q, Kenny K, Tollersrud T, Samartino L, Conde S, Draghi De Benitez G, Gall D, Perez B, Rojas X (2004) Enzyme immunoassay for the diagnosis of brucellosis: chimeric Protein A-Protein G as a common enzyme labeled detection reagent for sera for different animal species. Vet Microbiol 101:123&#8211;129<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vetmic.2004.02.014</pub-id><pub-id pub-id-type="pmid">15172695</pub-id></mixed-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevens</surname><given-names>MG</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>SC</given-names></name><name name-style="western"><surname>Cheville</surname><given-names>NF</given-names></name></person-group><article-title>Comparative analysis of immune responses in cattle vaccinated with Brucella abortus strain 19 or strain RB51</article-title><source>Vet Immunol Immunopathol</source><year>1995</year><volume>44</volume><fpage>223</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/0165-2427(94)05311-F</pub-id><pub-id pub-id-type="pmid">7747403</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luna-Martinez</surname><given-names>JE</given-names></name><name name-style="western"><surname>Mejia-Teran</surname><given-names>C</given-names></name></person-group><article-title>Brucellosis in Mexico: current status and trends</article-title><source>Vet Microbiol</source><year>2002</year><volume>90</volume><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/S0378-1135(02)00241-9</pub-id><pub-id pub-id-type="pmid">12414130</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorneles</surname><given-names>EM</given-names></name><name name-style="western"><surname>Teixeira-Carvalho</surname><given-names>A</given-names></name><name name-style="western"><surname>Araujo</surname><given-names>MS</given-names></name><name name-style="western"><surname>Lima</surname><given-names>GK</given-names></name><name name-style="western"><surname>Martins-Filho</surname><given-names>OA</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Lage</surname><given-names>AP</given-names></name></person-group><article-title>T lymphocytes subsets and cytokine pattern induced by vaccination against bovine brucellosis employing S19 calfhood vaccination and adult RB51 revaccination</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>6034</fpage><lpage>6038</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.08.060</pub-id><pub-id pub-id-type="pmid">25218192</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>Zeytun</surname><given-names>A</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name></person-group><article-title>Induction of specific cytotoxic lymphocytes in mice vaccinated with Brucella abortus RB51</article-title><source>Infect Immun</source><year>2001</year><volume>69</volume><fpage>5502</fpage><lpage>5508</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.9.5502-5508.2001</pub-id><pub-id pub-id-type="pmid">11500423</pub-id><pub-id pub-id-type="pmcid">PMC98663</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McEwen</surname><given-names>AD</given-names></name><name name-style="western"><surname>Samuel</surname><given-names>JMD</given-names></name></person-group><article-title>Brucella abortus: heat stable protective antigen revealed by adjuvant and present in a rough variant strain 45/20: immunization experiments on guinea pigs</article-title><source>Vet Rec</source><year>1955</year><volume>67</volume><fpage>546</fpage><lpage>548</lpage></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McEwen</surname><given-names>AD</given-names></name></person-group><article-title>Experiments on contagious abortion. The immunity of cattle inoculated with vaccines of graded virulence</article-title><source>Vet Rec</source><year>1940</year><volume>52</volume><fpage>815</fpage></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>B</given-names></name></person-group><article-title>The effect of immaturity of the calf on immunological responses to strain 19 and killed 45/20 adjuvant vaccines</article-title><source>Vet Rec</source><year>1977</year><volume>101</volume><fpage>283</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1136/vr.101.14.283</pub-id><pub-id pub-id-type="pmid">411231</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woodard</surname><given-names>LF</given-names></name><name name-style="western"><surname>Jasman</surname><given-names>RL</given-names></name></person-group><article-title>Comparative efficacy of an experimental S45/20 bacterin and a reduced dose of strain 19 vaccine against bovine brucellosis</article-title><source>Am J Vet Res</source><year>1983</year><volume>44</volume><fpage>907</fpage><lpage>910</lpage><pub-id pub-id-type="pmid">6870000</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name><name name-style="western"><surname>Hammerberg</surname><given-names>C</given-names></name><name name-style="western"><surname>Finkler</surname><given-names>BR</given-names></name></person-group><article-title>Monoclonal antibodies to Brucella surface antigens associated with the smooth lipopolysaccharide complex</article-title><source>Am J Vet Res</source><year>1984</year><volume>45</volume><fpage>967</fpage><lpage>971</lpage><pub-id pub-id-type="pmid">6203443</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivanov</surname><given-names>AV</given-names></name><name name-style="western"><surname>Salmakov</surname><given-names>KM</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>SC</given-names></name><name name-style="western"><surname>Plumb</surname><given-names>GE</given-names></name></person-group><article-title>A live vaccine from Brucella abortus strain 82 for control of cattle brucellosis in the Russian Federation</article-title><source>Anim Health Res Rev</source><year>2011</year><volume>12</volume><fpage>113</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1017/S1466252311000028</pub-id><pub-id pub-id-type="pmid">21676343</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><mixed-citation publication-type="other">Salmakov KM, Fomin AM, Plotnikova EM, Safina GM, Galimova GM, Salmakova AV, Ivanov AV, Panin AN, Sklyarov OD, Shumilov KV, Klimanov AI (2010) Comparative study of the immunobiological properties of live brucellosis vaccines. Vaccine 28(Suppl 5):F35&#8211;40<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2010.03.050</pub-id><pub-id pub-id-type="pmid">20362201</pub-id></mixed-citation></ref><ref id="CR84"><label>84.</label><mixed-citation publication-type="other">Li X, Xu J, Xie Y, Qiu Y, Fu S, Yuan X, Ke Y, Yu S, Du X, Cui M, Chen Y, Wang T, Wang Z, Yu Y, Huang K, Huang L, Peng G, Chen Z, Wang Y (2012) Vaccination with recombinant flagellar proteins FlgJ and FliN induce protection against Brucella abortus 544 infection in BALB/c mice. Vet Microbiol 161:137&#8211;144<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vetmic.2012.07.016</pub-id><pub-id pub-id-type="pmid">22854331</pub-id></mixed-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Du</surname><given-names>X</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Peng</surname><given-names>G</given-names></name><name name-style="western"><surname>Huang</surname><given-names>K</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name></person-group><article-title>Immunization of mice with recombinant protein CobB or AsnC confers protection against Brucella abortus infection</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0029552</pub-id><pub-id pub-id-type="pmid">22383953</pub-id><pub-id pub-id-type="pmcid">PMC3286461</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Onate</surname><given-names>AA</given-names></name><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>E</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>S</given-names></name><name name-style="western"><surname>Folch</surname><given-names>H</given-names></name></person-group><article-title>Vaccination with live Escherichia coli expressing Brucella abortus Cu/Zn superoxide dismutase protects mice against virulent B. abortus</article-title><source>Infect Immun</source><year>1999</year><volume>67</volume><fpage>986</fpage><lpage>988</lpage><pub-id pub-id-type="pmid">9916121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.67.2.986-988.1999</pub-id><pub-id pub-id-type="pmcid">PMC96417</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>Cravero</surname><given-names>S</given-names></name><name name-style="western"><surname>Calvert</surname><given-names>CL</given-names></name><name name-style="western"><surname>Toth</surname><given-names>TE</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name><name name-style="western"><surname>Rossetti</surname><given-names>OL</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name></person-group><article-title>Characterization of specific immune responses of mice inoculated with recombinant vaccinia virus expressing an 18-kilodalton outer membrane protein of Brucella abortus</article-title><source>Clin Vaccine Immunol</source><year>2000</year><volume>7</volume><fpage>114</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1128/CDLI.7.1.114-118.2000</pub-id><pub-id pub-id-type="pmcid">PMC95834</pub-id><pub-id pub-id-type="pmid">10618289</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edmonds</surname><given-names>M</given-names></name><name name-style="western"><surname>Booth</surname><given-names>N</given-names></name><name name-style="western"><surname>Hagius</surname><given-names>S</given-names></name><name name-style="western"><surname>Walker</surname><given-names>J</given-names></name><name name-style="western"><surname>Enright</surname><given-names>F</given-names></name><name name-style="western"><surname>Roop</surname><given-names>RM</given-names><suffix>2nd</suffix></name><name name-style="western"><surname>Elzer</surname><given-names>P</given-names></name></person-group><article-title>Attenuation and immunogenicity of a Brucella abortus htrA cycL double mutant in cattle</article-title><source>Vet Microbiol</source><year>2000</year><volume>76</volume><fpage>81</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/S0378-1135(00)00225-X</pub-id><pub-id pub-id-type="pmid">10925044</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Han</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Tian</surname><given-names>M</given-names></name><name name-style="western"><surname>Ding</surname><given-names>C</given-names></name><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name></person-group><article-title>Inactivation of the ABC transporter ATPase gene in Brucella abortus strain 2308 attenuated the virulence of the bacteria</article-title><source>Vet Microbiol</source><year>2013</year><volume>164</volume><fpage>322</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2013.02.017</pub-id><pub-id pub-id-type="pmid">23507429</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trant</surname><given-names>CG</given-names></name><name name-style="western"><surname>Lacerda</surname><given-names>TL</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>NB</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>V</given-names></name><name name-style="western"><surname>Rosinha</surname><given-names>GM</given-names></name><name name-style="western"><surname>Salcedo</surname><given-names>SP</given-names></name><name name-style="western"><surname>Gorvel</surname><given-names>JP</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>SC</given-names></name></person-group><article-title>The Brucella abortus phosphoglycerate kinase mutant is highly attenuated and induces protection superior to that of vaccine strain 19 in immunocompromised and immunocompetent mice</article-title><source>Infect Immun</source><year>2010</year><volume>78</volume><fpage>2283</fpage><lpage>2291</lpage><pub-id pub-id-type="doi">10.1128/IAI.01433-09</pub-id><pub-id pub-id-type="pmid">20194591</pub-id><pub-id pub-id-type="pmcid">PMC2863508</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Niu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name></person-group><article-title>In vivo differences in the virulence, pathogenicity, and induced protective immunity of wboA mutants from genetically different parent Brucella spp</article-title><source>Clin Vaccine Immunol</source><year>2013</year><volume>20</volume><fpage>174</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1128/CVI.00573-12</pub-id><pub-id pub-id-type="pmid">23239800</pub-id><pub-id pub-id-type="pmcid">PMC3571281</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajasekaran</surname><given-names>P</given-names></name><name name-style="western"><surname>Seleem</surname><given-names>MN</given-names></name><name name-style="western"><surname>Contreras</surname><given-names>A</given-names></name><name name-style="western"><surname>Purwantini</surname><given-names>E</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name></person-group><article-title>Brucella abortus strain RB51 leucine auxotroph as an environmentally safe vaccine for plasmid maintenance and antigen overexpression</article-title><source>Applied Environ Microbiol</source><year>2008</year><volume>74</volume><fpage>7051</fpage><lpage>7055</lpage><pub-id pub-id-type="doi">10.1128/AEM.01511-08</pub-id><pub-id pub-id-type="pmcid">PMC2583484</pub-id><pub-id pub-id-type="pmid">18836016</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name></person-group><article-title>Brucella abortus strain RB51 as a vector for heterologous protein expression and induction of specific Th1 type immune responses</article-title><source>Infect Immun</source><year>2000</year><volume>68</volume><fpage>3290</fpage><lpage>3296</lpage><pub-id pub-id-type="doi">10.1128/IAI.68.6.3290-3296.2000</pub-id><pub-id pub-id-type="pmid">10816476</pub-id><pub-id pub-id-type="pmcid">PMC97584</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramamoorthy</surname><given-names>S</given-names></name><name name-style="western"><surname>Sanakkayala</surname><given-names>N</given-names></name><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>Jain</surname><given-names>N</given-names></name><name name-style="western"><surname>Lindsay</surname><given-names>DS</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GS</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name></person-group><article-title>Prevention of vertical transmission of Neospora caninum in C57BL/6 mice vaccinated with Brucella abortus strain RB51 expressing N. caninum protective antigens</article-title><source>Int J Parasitol</source><year>2007</year><volume>37</volume><fpage>1531</fpage><lpage>1538</lpage><pub-id pub-id-type="doi">10.1016/j.ijpara.2007.04.021</pub-id><pub-id pub-id-type="pmid">17575983</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><mixed-citation publication-type="other">Sabio y Garc&#237;a JV, Bigi F, Rossetti O, Campos E (2010) Expression of MPB83 from Mycobacterium bovis in Brucella abortus S19 induces specific cellular immune response against the recombinant antigen in BALB/c mice. Microbes Infect 12:1236&#8211;1243<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micinf.2010.09.009</pub-id><pub-id pub-id-type="pmid">20888425</pub-id></mixed-citation></ref><ref id="CR96"><label>96.</label><mixed-citation publication-type="other">Sabio y Garc&#237;a JV, Farber M, Carrica M, Cravero S, Macedo GC, Bigi F, Oliveira SC, Rossetti O, Campos E (2008) Expression of Babesia bovis rhoptry-associated protein 1 (RAP1) in Brucella abortus S19. Microbes Infect 10:635&#8211;641<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micinf.2008.02.010</pub-id><pub-id pub-id-type="pmid">18462974</pub-id></mixed-citation></ref><ref id="CR97"><label>97.</label><mixed-citation publication-type="other">Avila-Calder&#243;n E, Araiza-Villanueva M, Cancino-Diaz J, L&#243;pez-Villegas E, Sriranganathan N, Boyle S, Contreras-Rodr&#237;guez A (2015) Roles of bacterial membrane vesicles. Arch Microbiol 197:1&#8211;10<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00203-014-1042-7</pub-id><pub-id pub-id-type="pmid">25294190</pub-id></mixed-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollak</surname><given-names>CN</given-names></name><name name-style="western"><surname>Delpino</surname><given-names>MV</given-names></name><name name-style="western"><surname>Fossati</surname><given-names>CA</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>PC</given-names></name></person-group><article-title>Outer membrane vesicles from Brucella abortus promote bacterial internalization by human monocytes and modulate their innate immune response</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0050214</pub-id><pub-id pub-id-type="pmid">23189190</pub-id><pub-id pub-id-type="pmcid">PMC3506553</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><mixed-citation publication-type="other">Lamontagne J, Butler H, Chaves-Olarte E, Hunter J, Schirm M, Paquet C, Tian M, Kearney P, Hamaidi L, Chelsky D, Moriyon I, Moreno E, Paramithiotis E (2007) Extensive cell envelope modulation is associated with virulence in Brucella abortus. J Proteome Res 6:1519&#8211;1529<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/pr060636a</pub-id><pub-id pub-id-type="pmid">17343405</pub-id></mixed-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain-Gupta</surname><given-names>N</given-names></name><name name-style="western"><surname>Contreras-Rodriguez</surname><given-names>A</given-names></name><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>Witonsky</surname><given-names>SG</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name></person-group><article-title>Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against Brucella melitensis challenge in mice</article-title><source>FEMS Immunol Med Microbiol</source><year>2012</year><volume>66</volume><fpage>436</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1111/1574-695X.12010</pub-id><pub-id pub-id-type="pmid">23163875</pub-id><pub-id pub-id-type="pmcid">PMC4426994</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>